123 related articles for article (PubMed ID: 22551139)
1. Everolimus in HR-positive advanced breast cancer.
Massarweh S; Croley J; Weiss H
N Engl J Med; 2012 May; 366(18):1738-9; author reply 1739-40. PubMed ID: 22551139
[No Abstract] [Full Text] [Related]
2. Everolimus in HR-positive advanced breast cancer.
Tartarone A; Lerose R; Aieta M
N Engl J Med; 2012 May; 366(18):1739; author reply 1739-40. PubMed ID: 22551140
[No Abstract] [Full Text] [Related]
3. BOLERO-2 - will this change practice in advanced breast cancer?
Johnston SR
Breast Cancer Res; 2012 Jun; 14(3):311. PubMed ID: 22713135
[TBL] [Abstract][Full Text] [Related]
4. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
5. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
[TBL] [Abstract][Full Text] [Related]
6. [BOLERO -- another remarkable step in treatment of breast cancer].
Rubovszky G; Láng I
Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Yi Z; Liu B; Sun X; Rong G; Wang W; Li H; Guan X; Li L; Zhai J; Li C; Qian H; Ma F; Xu B
Breast; 2020 Aug; 52():17-22. PubMed ID: 32335491
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant ovarian suppression in premenopausal breast cancer.
Montemurro F; Perrone F; Geuna E
N Engl J Med; 2015 Apr; 372(17):1672-3. PubMed ID: 25901438
[No Abstract] [Full Text] [Related]
10. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF
N Engl J Med; 2015 Apr; 372(17):1673. PubMed ID: 25901437
[No Abstract] [Full Text] [Related]
11. Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
Hershman DL
N Engl J Med; 2015 Jan; 372(5):477-8. PubMed ID: 25495491
[No Abstract] [Full Text] [Related]
12. [An advance in the management of breast cancer].
Soins; 2013 Apr; (774):12. PubMed ID: 23697050
[No Abstract] [Full Text] [Related]
13. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
14. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Burstein HJ; Griggs JJ
J Clin Oncol; 2012 Mar; 30(7):684-6. PubMed ID: 22271478
[No Abstract] [Full Text] [Related]
15. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
16. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.
Nicolatou-Galitis O; Nikolaidi A; Athanassiadis I; Papadopoulou E; Sonis S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Aug; 116(2):e110-6. PubMed ID: 23643584
[TBL] [Abstract][Full Text] [Related]
17. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
Gnant M
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1579-89. PubMed ID: 23253223
[TBL] [Abstract][Full Text] [Related]
18. Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Visy A; Bachelot T; Racadot S
Cancer Radiother; 2019 Sep; 23(5):423-425. PubMed ID: 31176579
[TBL] [Abstract][Full Text] [Related]
19. FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Wein L; Savas P; Van Geelen C; Caramia F; Moodie K; Joshi S; Loi S
Ann Oncol; 2017 Aug; 28(8):2025-2027. PubMed ID: 28430863
[No Abstract] [Full Text] [Related]
20. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Vicier C; Dieci MV; Andre F
Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
